

## AGENDA

*Uniform Formulary Beneficiary Advisory Panel  
25 March 2010 @ 9:00 AM*

*Naval Heritage Center Theater  
701 Pennsylvania Ave. NW., Washington DC 20004*

- **Administrative Meeting (BAP members only @ 7:30 A.M.)**
- **Elections**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

*Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.*

*The Committee made recommendations of the following drug classes during the Feb 2010 meeting:*

- *Drug Class Review:*
  - *Basal Insulins*
  - *Antihemophilic Factors*
    - *Factor VIII and Factor IX concentrates*
    - *Factor VIII/von Willebrand factor complexes, human prothrombin concentrate complexes, inhibitor bypassing products*
- *Designated Newly Approved Drugs*
  - *Narcotic Analgesics – Embeda (morphine extended release / naltrexone capsules)*
  - *Attention Deficit / Hyperactivity Disorder Drugs – Intuniv (guanfacine extended release tablets)*
  - *Newer Sedative Hypnotics – Edluar (zolpidem sublingual tablets)*
  - *Renin Angiotensin Antihypertensive Agents (RAAs) – Twynsta (telmisartan/amlodipine/tablets)*

- *Renin Angiotensin Antihypertensive Agents (RAAs) – Valtorna (aliskiren/valsartan tablets)*

- **Formulary status of drugs not in compliance with 2008 NDAA Section 703**

- **Panel Discussions**

*The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.*

- **Item for Information**

*Members of the DoD Pharmacoeconomic Center will present an informational discussion of the following:*

- *FY 09 Uniform Formulary Performance*